Hims & Hers Health Raises Outlook, Swings to 3Q Profit
Hims & Hers Health (HIMS.US) will launch a generic version of the old weight loss therapy of novo-nordisk a/s (NVO.US).
Hims & Hers Health CEO Andrew Dudum stated that the company is preparing to launch a non-patented version of novo-nordisk a/s's old version GLP-1 weight loss therapy liraglutide in 2025.
Hims & Hers Health Options Spot-On: On November 5th, 162.7K Contracts Were Traded, With 342.86K Open Interest
On November 5th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 162.7K options for the day, of which put options accounted for 46.37% of the total
Hims & Hers Stock Rises on Earnings and Planned Generic Version of Novo Nordisk Diabetes Drug -- Barrons.com
What's Going On With Hims & Hers Health Stock Tuesday?
Hims & Hers Core Business Looked Strong in 3Q -- Market Talk